Annual Report 2016



Annual Report 2016



Annual Report 2016

Research centre for

cancer, neurosciences

and translational medicine.


The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center established in 2004. Its stakeholders are Bellvitge University Hospital and Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, University of Barcelona and the City of L’Hospitalet de Llobregat.

IDIBELL is located in L’Hospitalet de Llobregat, south of Barcelona. It is a member of the Campus of International Excellence of the University of Barcelona HUBc and part of the CERCA institution of the Generalitat of Catalonia. In 2009, it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Institute of Health. The European Commission has granted IDIBELL the ‘HR Excellence in Research‘ logo for its continuous improvement of its human resources policies in accordance with the principles of the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers.

A key aspect of research in IDIBELL is its proximity to the patient. Because of its location and the healthcare activity that many of its researchers carry out, IDIBELL research groups can identify which problems are really priority and which solutions are effective in daily clinical practice.

IDIBELL is located in the Bellvitge Campus area, a biomedical and biotechnology cluster of health care facilities, knowledge-generating institutions, research centres and companies of the sector of life sciences and health in constant growth; an area that is becoming one of the most dynamic and innovative places in the country in terms of health and biomedical research.


Bellvitge University Hospital

Viladecans Hospital – GTMS

Catalan Institute of Oncology

University of Barcelona (Bellvitge)

Our trustees

The Board of Trustees, the highest governing body of IDIBELL, approves and supervises the annual budget and the strategic plan for the institute.

Conseller de Salut, Generalitat de Catalunya
Antoni Comín Oliveres

1st Vicepresident
Conseller d’Economia i Coneixement
Jordi Baiget Cantons

2nd Vicepresident
Rector de la Universitat de Barcelona
Joan Elias García

Gerent de l’Hospital Universitari de Bellvitge, Institut Català de Salut
Montserrat Figuerola Batista

Appointed by Departament de Salut
Antoni Andreu Périz
Jaume Reventós Puigjaner

Appointed by Departament d’Economia i Coneixement
Francesc Subirada Curcó
Lluís Rovira Pato
Iolanda Font de Rubinat Garcia
Arcadi Navarro Cuartiellas

Appointed by la Universitat de Barcelona
Domènec Espriu Climent
Mercè Pallàs Lliberia

Appointed by l’Ajuntament de L’Hospitalet de Llobregat
Núria Marin Martínez

Appointed by lnstitut Català d’Oncologia
Josep M. Vilà Cortasa
Josep Ramón Germà Lluch

Appointed by Hospital Universitari de Bellvitge
Cristina Capdevila Aguilera


Organization chart

The Board of Trustees, the highest governing body of IDIBELL, is chaired by the Minister of Health. The Board of Trustees bears the highest level of representation for the institution. Among its functions are approving and supervising the annual budget and the strategic plan for the institute.
The external Scientific Advisory Board (SAB) plays the role of advising the Board of Trustees of IDIBELL, thereby ensuring the scientific quality of the institute. The SAB is composed of world-renowned researchers from other national and European institutions. President: Paolo Gasparini; Secretary: Lisardo Boscà; Members: Ernest Arenas, Robert Sackstein, Ana Aranda and Sonia Martínez
The Executive Board carries out the periodical monitoring of administrative and management activities of the institute, in addition to functions delegated to it by the Board of Trustees. President: Antoni Andreu; Secretary: Montserrat Figuerola; Vocals: Francesc Subirada, Josep Ramón Germà, Domènec Espriu, Lluís Rovira
IDIBELL’s research is organized into three different areas and nine research programs within them, including about sixty-five research groups.
The IDIBELL Core Facilities include a set of centralized platforms dedicated to developing and providing research resources to assist campus biomedical researchers. Our research facilities offer a number of services, ranging from genomics or proteomics to our animal facility. Specific hospital associated platforms, such as biobank and clinical trials are also a hallmark. Through these different resources, we supply equipment and instrumentation, technical expertise and training to promote innovative, cutting edge research. They are accessible on a basis of fee for service to the entire IDIBELL community, as well as external institutions and private companies
The executive committee consists of: CEO: Jaume Reventós / Gabriel Capellá; Scientific director: Josep Manuel Menchón; Managing director: Alexandre Puerto / Magda Martí; Scientific office manager: Marina Rigau; Innovation & Business director: Raquel Egea; HHRR director: Esther Comabella; Core facilitites manager: Mercè Martí

Financial information


27.760.129 €
Competitive projects
10.681.841 €
Clinical trials and agreements
10.339.771 €
Services and other
1.203.507 €
Non-competitive income - Health Department
4.800.000 €
Non-competitive income - Trustees
180.304 €
Non-competitive income - other
554.706 €
Equity - negative results
0 €


27.760.129 €
14.596.141 €
Services and Goods
6.564.968 €
6.548.009 €
Equity - positive results
51.011 €